Whalesbook
Semaglutide Approval Validates OneSource's CDMO Role
OneSource Specialty Pharma (ONEO) is set to benefit from Health Canada's April 29, 2026, approval of Dr. Reddy's Laboratories' generic semaglutide injection. As the exclusive contract development and manufacturing organization (CDMO) for this product, OneSource's Bengaluru facility is key to supplying this complex peptide therapeutic to a major regulated market. The approval validates OneSource's advanced manufacturing skills for complex peptide injectables, a segment with strong global demand. The Canadian semaglutide market, estimated at 12 million units annually, offers a significant opportunity, with Dr. Reddy's being the first to receive market authorization in a G7 nation.
Scaling Up for Peptide Demand
OneSource's strategic focus on complex injectables and biologics seems timely. The global peptide therapeutics market is forecast to reach $100 billion by 2034, fueled by demand for treatments in oncology, diabetes, and obesity. The company is investing about $100 million in new production lines to meet this growing demand. OneSource offers end-to-end services, from cartridge filling to device assembly, a niche it says has limited competition in India. This integrated approach sets it apart in the CDMO market, which generated $2.8 billion globally in 2024 and is expected to exceed $8 billion by 2033. OneSource has also secured SFDA approval for generic Ozempic in Saudi Arabia with Hikma Pharmaceuticals.
However, OneSource's growth plans face intense competition and a rapidly changing regulatory environment. The lucrative U.S. market, a significant step beyond Canada, will remain largely inaccessible for generics until the early 2030s due to patent expirations. The company's valuation reflects aggressive growth expectations; its trailing twelve-month (TTM) P/E ratio of around 119.06x is much higher than peers such as Dr. Reddy's (19.94x) or Sun Pharma (35.33x), indicating investors expect substantial future success.
Concerns Over Past Performance and Valuation
Despite positive forecasts, OneSource Specialty Pharma faces significant risks. Its stock has reportedly declined over the past decade due to earnings problems. Recent financials were weak, with Q3FY26 revenue falling 26% year-over-year and EBITDA dropping 88%, largely due to delayed semaglutide approvals in Canada. This shows a high reliance on partner and regulatory timelines. A low interest coverage ratio and a three-year return on equity (ROE) of -17.7% highlight this vulnerability. Additionally, promoters have pledged 38.4% of their holdings, often signaling financial pressure. The company's market capitalization is around ₹20,212 Cr. as of April 2026, a substantial figure given its volatile earnings history and a P/E multiple that is higher than industry leaders.
Analyst Outlook: Cautious Optimism for Growth
Analysts hold a cautiously optimistic view, with a consensus rating favoring 'Buy' for OneSource Specialty Pharma. The average 12-month price target from analysts is around INR 1,943.50, suggesting a potential upside of roughly 9.89%. Forecasts predict strong future growth, with revenue and earnings per share anticipated to rise by 42.7% and 120.3% annually. However, recent reports show a 24% drop in consensus revenue estimates from January 2026, indicating potential short-term challenges. The company's projected return on equity in three years is forecast at 11.3%, which is positive but modest compared to expected earnings growth. OneSource's FY28 revenue target of $400 million would mark significant expansion, but relies on continued regulatory approvals and market penetration for its CDMO services in the complex peptide sector.